• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗4-1BB单克隆抗体诱导的荷黑素瘤小鼠中CD11c+CD8+ T细胞显著扩增。

Marked expansion of CD11c+CD8+ T-cells in melanoma-bearing mice induced by anti-4-1BB monoclonal antibody.

作者信息

Ju Seong-A, Park Sang-Min, Lee Sang-Chul, Kwon Byoung S, Kim Byung-Sam

机构信息

Department of Biological Sciences and Immunomodulation Research Center, University of Ulsan, Ulsan 680-749, Korea.

出版信息

Mol Cells. 2007 Aug 31;24(1):132-8.

PMID:17846508
Abstract

4-1BB (CD137), a member of the tumor necrosis factor receptor superfamily, is expressed on activated T-cells, and 4-1BB signaling due to interaction with 4-1BB ligand or ligation with anti-4-1BB monoclonal antibody (mAb) costimulates T cells. It has been shown that administration of anti-4-1BB mAb induces anti-tumor immunity in mice, but the nature of the cellular subsets responsible for this immunity is uncertain. In this study we found that anti-4-1BB mAb administration to B16F10 melanoma-bearing mice induced marked expansion of CD11c+CD8+ T-cells in parallel with suppression of pulmonary tumors. The mAb-treated mice produced higher levels of IFN- in their tumor tissues, spleen and lymph nodes than mice exposed to control antibody. When the CD11c+CD8+ T-cells were purified and re-stimulated in vitro, they produced high levels of the Th1 cytokines, IFN- and IL-2, but low levels of the Th2 cytokines, IL-4 and IL-10. Furthermore, they expressed high levels of 4-1BB and CD107a, a marker of activated cytotoxic T-lymphocytes. Our results suggest that CD11c+CD8+ T-cells play a role in the anti-tumor immunity induced by anti-4-1BB mAb.

摘要

4-1BB(CD137)是肿瘤坏死因子受体超家族的成员,在活化的T细胞上表达,与4-1BB配体相互作用或用抗4-1BB单克隆抗体(mAb)进行连接所引发的4-1BB信号传导可共刺激T细胞。已有研究表明,给予抗4-1BB mAb可在小鼠中诱导抗肿瘤免疫,但负责这种免疫的细胞亚群的性质尚不确定。在本研究中,我们发现给携带B16F10黑色素瘤的小鼠施用抗4-1BB mAb可诱导CD11c + CD8 + T细胞显著扩增,同时抑制肺部肿瘤。与接受对照抗体的小鼠相比,用mAb处理的小鼠在其肿瘤组织、脾脏和淋巴结中产生更高水平的干扰素。当CD11c + CD8 + T细胞在体外纯化并重新刺激时,它们产生高水平的Th1细胞因子干扰素和白细胞介素-2,但产生低水平的Th2细胞因子白细胞介素-4和白细胞介素-10。此外,它们高水平表达4-1BB和CD107a,后者是活化的细胞毒性T淋巴细胞的标志物。我们的结果表明,CD11c + CD8 + T细胞在抗4-1BB mAb诱导的抗肿瘤免疫中发挥作用。

相似文献

1
Marked expansion of CD11c+CD8+ T-cells in melanoma-bearing mice induced by anti-4-1BB monoclonal antibody.抗4-1BB单克隆抗体诱导的荷黑素瘤小鼠中CD11c+CD8+ T细胞显著扩增。
Mol Cells. 2007 Aug 31;24(1):132-8.
2
Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumour-infiltrating lymphocytes.由4-1BB介导的黑色素瘤免疫与肿瘤浸润淋巴细胞活性增强有关。
Immunol Cell Biol. 2005 Aug;83(4):344-51. doi: 10.1111/j.1440-1711.2005.01330.x.
3
Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.CD137/4-1BB 通路共刺激可保护人黑色素瘤肿瘤浸润淋巴细胞免于激活诱导的细胞死亡,并增强抗肿瘤效应功能。
J Immunother. 2011 Apr;34(3):236-50. doi: 10.1097/CJI.0b013e318209e7ec.
4
Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.4-1BB/CD137 共刺激可改善过继性 T 细胞治疗中 CD8(+)黑色素瘤肿瘤浸润淋巴细胞的扩增和功能。
PLoS One. 2013;8(4):e60031. doi: 10.1371/journal.pone.0060031. Epub 2013 Apr 1.
5
NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.通过白细胞介素-12基因疗法和4-1BB共刺激的联合作用,自然杀伤细胞和CD8 + T细胞介导对免疫原性较差的B16-F10黑色素瘤的清除。
Int J Cancer. 2004 Apr 20;109(4):499-506. doi: 10.1002/ijc.11696.
6
Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy.抗4-1BB和抗CD4疗法协同抗癌免疫的相关机制。
Cancer Res. 2007 Sep 15;67(18):8891-9. doi: 10.1158/0008-5472.CAN-07-1056.
7
4-1BB Agonism Combined With PD-L1 Blockade Increases the Number of Tissue-Resident CD8+ T Cells and Facilitates Tumor Abrogation.4-1BB激动剂与PD-L1阻断联合使用可增加组织驻留CD8 + T细胞数量并促进肿瘤消除。
Front Immunol. 2020 Apr 24;11:577. doi: 10.3389/fimmu.2020.00577. eCollection 2020.
8
Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function.4-1BB 共刺激受体抗体通过耗竭调节性 T 细胞和促进 CD8+T 细胞效应功能增强抗肿瘤免疫。
Immunity. 2018 Nov 20;49(5):958-970.e7. doi: 10.1016/j.immuni.2018.09.014. Epub 2018 Nov 13.
9
Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease.给予激动型抗4-1BB单克隆抗体可改善炎症性肠病。
Immunol Lett. 2005 Nov 15;101(2):210-6. doi: 10.1016/j.imlet.2005.06.001.
10
Origins and functional basis of regulatory CD11c+CD8+ T cells.调节性CD11c+CD8+ T细胞的起源及功能基础。
Eur J Immunol. 2009 Jun;39(6):1552-63. doi: 10.1002/eji.200839057.

引用本文的文献

1
Identifying conserved metastatic pathways across cancers through integrated transcriptomic and network analysis.通过整合转录组学和网络分析来识别跨癌症的保守转移途径。
Med Oncol. 2025 Jul 10;42(8):321. doi: 10.1007/s12032-025-02902-2.
2
Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4-1BBL induces systemic anti-tumor immunity.瘤内递送脂质纳米颗粒配制的编码IL-21、IL-7和4-1BBL的mRNA可诱导全身抗肿瘤免疫。
Nat Commun. 2024 Dec 6;15(1):10635. doi: 10.1038/s41467-024-54877-9.
3
Brief Communication: Combination of an MIP3α-Antigen Fusion Therapeutic DNA Vaccine With Treatments of IFNα and 5-Aza-2'Deoxycytidine Enhances Activated Effector CD8+ T Cells Expressing CD11c in the B16F10 Melanoma Model.
简短通讯:在B16F10黑色素瘤模型中,MIP3α - 抗原融合治疗性DNA疫苗与IFNα和5 - 氮杂 - 2'-脱氧胞苷联合治疗可增强表达CD11c的活化效应CD8 + T细胞。
J Immunother. 2025 Jan 1;48(1):1-5. doi: 10.1097/CJI.0000000000000542. Epub 2024 Oct 14.
4
Combination of a MIP3α-antigen fusion therapeutic DNA vaccine with treatments of IFNα and 5-Aza-2'Deoxycytidine enhances activated effector CD8+ T cells expressing CD11c in the B16F10 melanoma model.在B16F10黑色素瘤模型中,MIP3α-抗原融合治疗性DNA疫苗与IFNα和5-氮杂-2'-脱氧胞苷联合治疗可增强表达CD11c的活化效应CD8+ T细胞。
Res Sq. 2024 Aug 20:rs.3.rs-3243336. doi: 10.21203/rs.3.rs-3243336/v2.
5
Anti-4-1BB antibody-based combination therapy augments antitumor immunity by enhancing CD11cCD8 T cells in renal cell carcinoma.基于抗4-1BB抗体的联合疗法通过增强肾细胞癌中的CD11cCD8 T细胞来增强抗肿瘤免疫力。
Oncol Lett. 2022 Feb;23(2):43. doi: 10.3892/ol.2021.13161. Epub 2021 Dec 6.
6
B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8 tumor-infiltrating lymphocytes.B7-H3×4-1BB 双特异性抗体通过增强终末分化的 CD8 肿瘤浸润淋巴细胞增强抗肿瘤免疫。
Sci Adv. 2021 Jan 15;7(3). doi: 10.1126/sciadv.aax3160. Print 2021 Jan.
7
Growth differentiation factor-15 slows the growth of murine prostate cancer by stimulating tumor immunity.生长分化因子 15 通过刺激肿瘤免疫来减缓小鼠前列腺癌的生长。
PLoS One. 2020 Jun 5;15(6):e0233846. doi: 10.1371/journal.pone.0233846. eCollection 2020.
8
Tumoricidal efficacy coincides with CD11c up-regulation in antigen-specific CD8(+) T cells during vaccine immunotherapy.在疫苗免疫治疗期间,肿瘤杀伤功效与抗原特异性CD8(+) T细胞中CD11c上调相一致。
J Exp Clin Cancer Res. 2016 Sep 13;35(1):143. doi: 10.1186/s13046-016-0416-x.
9
4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity.4-1BB激动剂:肿瘤免疫的多能增强剂。
Front Oncol. 2015 Jun 8;5:117. doi: 10.3389/fonc.2015.00117. eCollection 2015.
10
The anti-lymphoma activities of anti-CD137 monoclonal antibodies are enhanced in FcγRIII(-/-) mice.抗CD137单克隆抗体的抗淋巴瘤活性在FcγRIII(-/-)小鼠中增强。
Cancer Immunol Immunother. 2014 Sep;63(9):947-58. doi: 10.1007/s00262-014-1567-2. Epub 2014 Jun 14.